HGH Fragment 176-191

HGH Fragment 176-191 is a spliced variant of native human growth hormone. Specifically, it is made of the last 16 amino acids on GH's long 191 amino acid sequence. This fragment seems to retain some (not all) of the biological activity of growth hormone. On the one hand, the compound is no longer able to bind with the cellular GH receptor. As such, it does not elevate serum IGF-1, nor appear to have anabolic effects. On the other, it may still have distinct lipolytic (fat loss) properties. A drug like this could be applicable in situations where fat loss is desired, but GH's wider spectrum of anabolic effects (and potential side effects) is not. In the fitness community, this substance is used exclusively for fat loss. The exact mechanism of action for HGH Fragment 176-191 is unclear. This compound has not been the subject of extensive clinical study. Investigations into similar HGH fragments with the same active terminal amino acid sequence (178-191) suggest it may stimulate the protein kinase C pathway, and modulate hormone-sensitive lipase (HSL) and acetyl-CoA carboxylase. Note that HGH Fragment 176-191 is widely confused with AOD9604. The latter compound is actually a synthetic variant of the 177-191 amino acid sequence of growth hormone, with an additional tyrosine at the end.They are similar, though not the same compound. The efficacy of HGH Fragment 176-191 as a fat loss agent in humans has not yet been substantiated with clinical study. Its use in the fitness community is largely based on anecdotal reports and speculative information extrapolated from animal studies and clinical trials on related compounds. Still, while not exceedingly popular, HGH Fragment 176-191 remains a prominent feature in the unregulated market for peptide drugs. This may speak to its efficacy, at least to some degree.

Brand name HGH Fragment 176-191

HGH Fragment 176-191 Key Points

  • May mimic GH's lipolytic effect
  • Not anabolic
  • Short acting
  • Efficacy in humans unclear

HGH Fragment 176-191 History

HGH Fragment 176-191 was first described in 1976 by Bornstein. This drug was synthesized, and subsequently investigated, alongside a series of other related GH fragments. Many of these appeared to retain GH's effect on lipolysis, at least those possessing the same terminal sequence of 14 amino acids. HGH Fragment 176-191 appeared in a handful of studies going into the early 1980s. At that point, its further development seemed to have stalled. AOD9604, an analog of this drug, did appear in clinical trials during the 1990s. As of yet, however, it has not been approved as a drug product. HGH Fragment 176-191 also does not appear to be under clinical development at this time.

How is HGH Fragment 176-191 Supplied

This drug is not available as a pharmaceutical product. Standard dosage information is unavailable.

HGH Fragment 176-191 can be purchased as a research compound only. It is typically supplied in multi-dose vials containing 2, 5, or 10 mg of dry lyophilized powder. This must be reconstituted with saline or bacteriostatic water before use. All unused portions of this drug should be kept under refrigeration.

Structural Characteristics of HGH Fragment 176-191

HGH Fragment 176-192 is a truncated polypeptide consisting of the 16 amino-acid terminal chain of human growth hormone. Its exact sequence is Phe-Leu-Arg-lle-Val-GIn-Cys-Arg-Ser-Val-Glu-Gly-Ser-Cys-Gly-Phe.

HGH Fragment 176-191 Warnings

HGH Fragment 176-191 is an unapproved new drug. A thorough understanding of its safety and propensity for side effects in humans is lacking at this time.

HGH Fragment 176-191 Side Effects (General)

According to anecdotal reports, the most common side effects to HGH Fragment 176-191 include sleepiness and lethargy. Injection site reactions are also highly prominent (See below). Otherwise, the safety and adverse reaction profile of this drug are not fully characterized at this time.

HGH Fragment 176-191 Side Effects (Injection site)

The subcutaneous administration of this drug may cause redness, itching, pain, and/or lumps at the site of injection.

HGH Fragment 176-191 Administration

HGH Fragment 176-191 is generally given via subcutaneous (SC) injection.

This drug is not available as a pharmaceutical product. Standard dosage information is unavailable.

When used for physique-enhancing purposes, HGH Fragment 176-191 is usually administered at a dosage of 0.25 to .5 mg (250-500 meg) per injection. This may be given 1-2 times daily, usually on an empty stomach. One dosing episode is typically 30-60 minutes before cardio training, which may further intensify its fat loss effects. Total daily dosage generally does not exceed 1,000 meg.

Cycles of HGH Fragment 176-191 usually last 2-3 months, though longer programs are not uncommon.

HGH Fragment 176-191 Availability

HGH Fragment 176-191 is not available as a prescription drug product. It is sold exclusively as a "research compound" or gray market supplement. Note that the quality of gray market products can be difficult to assure.


Wlliam Llewellyn (2017) - Anabolics

Your experience with HGH Fragment 176-191

There are no comments yet.